The objective of this study is to make Dermacyte Liquid available on an expanded access basis to treat cutaneous ulcers and wounds refractory to initial treatment or that do not have adequate alternative treatments. Minimal data will be collected to evaluate the efficacy and safety of Dermacyte Liquid.
Must be 18 years of age or older
Must have a cutaneous ulcer or wound refractory to initial treatment or does not have an adequate treatment alternative, as determined by the Investigator
Must not be pregnant or lactating
Must not have known malignancies
Must not be less than 18 years of age
MTX-001 (Dermacyte Liquid)
DrugRepeat dose subcutaneous drug injection for the treatment of serious chronic wounds.
Click on the lead sponsor to view all of their trials.
